leisure time -WSS

leisure time

author：leisure time 2025-10-01 22:59:25 - browse：35

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Readout LOUD podcast: mifepristone case, GLP

WSS

States should stop sabotaging methadone treatment reform

Readout LOUD podcast: mifepristone case, GLP

Washington mulls new rules to avert another Change Healthcare

New Medicare drug pricing powers could soon be upended in court

Covid vaccine financial winners and losers, from Pfizer to Novavax

Idaho abortion case may prompt more restrictions in other states

focus

leisure time

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Washington mulls new rules to avert another Change Healthcare

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Merck, Vertex, and Viking updates

Walensky prepares to leave CDC — and Congress — behind

Readout LOUD podcast: live from JPM 2024

Medical records are filled with copy

Roche subsidiary Foundation Medicine opens new headquarters

23andMe had bad news about my health. I wish a person had delivered it

New England Journal of Medicine addresses racist history, slavery

focus

Patient advocates debate FDA's accelerated approval process

HHS names first

There's no autism epidemic. It's an autism diagnosis epidemic

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Caregivers of transplant patients call for more support, training

New menopause drug shows promise in relief for hot flashes

entertainment

entertainment

focus

entertainment